Takeda Pharmaceutical
362 hedge funds and large institutions have $1.82B invested in Takeda Pharmaceutical in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 177 increasing their positions, 56 reducing their positions, and 39 closing their positions.
2,078% more call options, than puts
Call options by funds: $30.6M | Put options by funds: $1.41M
216% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 56
46% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 39
39% more capital invested
Capital invested by funds: $1.31B → $1.82B (+$513M)
3% more funds holding
Funds holding: 350 → 362 (+12)
0.46% more ownership
Funds ownership: 2.65% → 3.11% (+0.46%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$113M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$98.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.7M |
| 4 |
CWP
Capital Wealth Planning
Naples,
Florida
|
+$15.6M |
| 5 |
Goldman Sachs
New York
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$45M |
| 2 |
D.E. Shaw & Co
New York
|
-$29.7M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24.3M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$15M |
| 5 |
Millennium Management
New York
|
-$13.9M |
TAK Hedge Fund Activity: Q1 2026 in Review
362 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2026, worth a combined $1.82B — up 39% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new TAK positions and 39 closed out — a net gain of 18 holders — while 177 added to existing stakes and 56 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $113M. The largest seller was Arrowstreet Capital, cutting an estimated $45M.
- 362 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2026, up from 350 in Q4 2025.
- Funds reported $1.82B of Takeda Pharmaceutical stock for Q1 2026, up 39% quarter-over-quarter.
- 57 funds opened new Takeda Pharmaceutical positions in Q1 2026 and 39 closed out, a net change of +18 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2026 was Adage Capital Partners, an estimated $113M added.
- The largest Takeda Pharmaceutical seller in Q1 2026 was Arrowstreet Capital, an estimated $45M sold.
Based on aggregated 13F filings for Q1 2026.